A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.